The Pharmacy Times® Neurology Resource Center is a comprehensive resource for clinical news and expert insights on disorders of the nervous system, including multiple sclerosis, Alzheimer disease, migraine, and Parkinson disease.
September 10th 2025
Selumetinib gains expanded FDA approval for younger pediatric patients with neurofibromatosis type 1 plexiform neurofibromas, enhancing treatment options and addressing significant disease-related challenges.
Clinical Overview: Comparison of Anti-Amyloid Monoclonal Antibodies for Alzheimer Disease
October 11th 2023Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.
Read More
Large Review Suggests IVIG is Effective for Neurological Diseases Following COVID-19 Infection
September 27th 2023Intravenous immunoglobulin found to provide fast and long-lasting relief for COVID-19-related neurological conditions, although investigators are still uncovering the pathology of many of these conditions.
Read More
Anti-Amyloid Monoclonal Antibody Drugs Continue to Show Promise Treating Alzheimer Disease
July 24th 2023New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.
Read More